Privium Fund Management B.V. Boosts Stake in Axsome Therapeutics, Inc. $AXSM

Privium Fund Management B.V. boosted its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 7.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,878 shares of the company’s stock after buying an additional 4,146 shares during the period. Axsome Therapeutics accounts for about 1.9% of Privium Fund Management B.V.’s investment portfolio, making the stock its 17th biggest holding. Privium Fund Management B.V.’s holdings in Axsome Therapeutics were worth $10,388,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Axsome Therapeutics by 6.0% during the third quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock worth $507,739,000 after buying an additional 235,626 shares during the period. Franklin Street Advisors Inc. NC purchased a new stake in Axsome Therapeutics during the fourth quarter worth $1,826,000. Aberdeen Group plc lifted its holdings in Axsome Therapeutics by 15.5% during the third quarter. Aberdeen Group plc now owns 94,648 shares of the company’s stock worth $11,495,000 after buying an additional 12,732 shares during the period. TD Asset Management Inc lifted its holdings in Axsome Therapeutics by 107.7% during the third quarter. TD Asset Management Inc now owns 44,192 shares of the company’s stock worth $5,367,000 after buying an additional 22,914 shares during the period. Finally, Pictet Asset Management Holding SA lifted its holdings in Axsome Therapeutics by 20.4% during the fourth quarter. Pictet Asset Management Holding SA now owns 436,063 shares of the company’s stock worth $79,643,000 after buying an additional 73,925 shares during the period. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Stock Down 0.3%

NASDAQ:AXSM opened at $223.06 on Wednesday. The company has a market cap of $11.47 billion, a PE ratio of -59.80 and a beta of 0.59. Axsome Therapeutics, Inc. has a twelve month low of $96.09 and a twelve month high of $234.29. The company has a current ratio of 1.55, a quick ratio of 1.48 and a debt-to-equity ratio of 1.38. The company’s 50 day moving average is $171.73 and its two-hundred day moving average is $163.34.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.41). The company had revenue of $191.20 million for the quarter, compared to analysts’ expectations of $191.10 million. Axsome Therapeutics had a negative return on equity of 246.90% and a negative net margin of 26.59%.Axsome Therapeutics’s revenue was up 57.4% on a year-over-year basis. Analysts anticipate that Axsome Therapeutics, Inc. will post -1.05 EPS for the current year.

Insiders Place Their Bets

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 233 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $228.18, for a total transaction of $53,165.94. Following the sale, the chief operating officer owned 4,517 shares of the company’s stock, valued at approximately $1,030,689.06. The trade was a 4.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Ari Maizel sold 7,500 shares of Axsome Therapeutics stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $182.42, for a total transaction of $1,368,150.00. Following the sale, the insider owned 7,500 shares of the company’s stock, valued at approximately $1,368,150. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 72,628 shares of company stock valued at $12,205,662. Insiders own 20.60% of the company’s stock.

More Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Very strong top-line growth — 1Q net product revenue of $191.2M, up ~57% YoY, driven by AUVELITY ($153.2M) and SUNOSI ($33.9M); this validates commercial traction for Axsome’s lead products. Axsome 1Q 2026 Financial Results
• Positive Sentiment: Multiple analyst price-target lifts today (notably Mizuho to $310, Wells Fargo to $255, Baird to $246, Morgan Stanley to $242) and continued “buy/outperform” coverage increase perceived upside and support near-term sentiment. Analyst Coverage & Price Target Moves
• Positive Sentiment: Pipeline and corporate catalysts remain in play — AUVELITY approval for agitation in Alzheimer’s, NDA submission for AXS‑12 (cataplexy), addition of AXS‑20 to the pipeline — these can drive medium/long-term upside. Business Update & Pipeline Highlights
• Neutral Sentiment: Management outreach: Axsome will participate in multiple investor conferences (BofA fireside chat, others) — useful for additional disclosure but timing/impact is uncertain. Investor Conference Participation
• Neutral Sentiment: Full earnings and call transcripts are available for deeper read-throughs; analysts and commentators are parsing sequential trends and guidance in detail. Earnings Call Transcript & Analysis
• Negative Sentiment: Earnings miss: GAAP EPS of ($1.26) vs. consensus (~$0.85 loss) — the wider loss and negative margins/ROE raise near-term profitability concerns despite revenue strength. Q1 Loss Widens; Revenues Jump (Zacks)
• Negative Sentiment: Some skepticism on sustainability — commentary notes sequential sales dips for key products and questions about achievability of management’s long‑term peak revenue targets, which could temper enthusiasm. Earnings Review & Skepticism (Seeking Alpha)

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on AXSM. Jefferies Financial Group lifted their price objective on shares of Axsome Therapeutics from $245.00 to $275.00 and gave the stock a “buy” rating in a research report on Monday. UBS Group boosted their price objective on shares of Axsome Therapeutics from $251.00 to $259.00 and gave the stock a “buy” rating in a research note on Friday, April 10th. Cantor Fitzgerald reiterated an “overweight” rating and set a $272.00 price objective on shares of Axsome Therapeutics in a research note on Monday. HC Wainwright set a $290.00 price objective on shares of Axsome Therapeutics in a research note on Tuesday. Finally, Needham & Company LLC set a $267.00 price objective on shares of Axsome Therapeutics and gave the stock a “buy” rating in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $251.89.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.